Neos Therapeutics

Neos Therapeutics is an oral drug delivery company developing controlled time-release technologies. The Company develops, manufactures, and commercializes innovative extended-release products using its proprietary extended-release drug delivery and orally disintegrating tablet (ODT) technology platforms. 

Neos Therapeutics has two FDA-approved products for the treatment of ADHD and both utilize its extended-release ODT technology.

The Company's growing ADHD Product Portfolio puts Neos in a unique position to meet the different needs of patients that struggle with ADHD.

Company Growth (employees)
Grand Prairie, US
Size (employees)
134 (est)+66%
Neos Therapeutics was founded in 2008 and is headquartered in Grand Prairie, US

Neos Therapeutics Office Locations

Neos Therapeutics has offices in Grand Prairie and Blue Bell
Grand Prairie, US (HQ)
2940 N. Highway 360
Blue Bell, US
130 1787 Sentry Pkwy W

Neos Therapeutics Data and Metrics

Neos Therapeutics Financial Metrics

Neos Therapeutics's revenue was reported to be $9.2 m in FY, 2016

Net income (Q1, 2017)

(17.1 m)

EBIT (Q1, 2017)

(15 m)

Market capitalization (21-Sep-2017)

202.4 m

Cash (31-Mar-2017)

43.7 m
Neos Therapeutics's current market capitalization is $202.4 m.
USDFY, 2015FY, 2016


3.8 m9.2 m

Revenue growth, %


Cost of goods sold

5.5 m11.4 m

Gross profit

(1.8 m)(2.3 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


1.5 m221 k

Cost of goods sold

2.3 m1.7 m2.3 m4.6 m

R&D expense

2.1 m2.7 m2.3 m4.3 m2.9 m1.7 m

General and administrative expense

1.7 m2.1 m3.6 m3.5 m3.1 m3.5 m
USDFY, 2015FY, 2016


90.8 m24.4 m

Accounts Receivable

1.2 m


2.5 m5.8 m

Current Assets

98.2 m55.3 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


25.6 m102.9 m42.4 m41.9 m43.5 m43.7 m


1.7 m2.7 m2.5 m4.4 m5.7 m5.6 m

Current Assets

29.7 m106.4 m93.1 m91.9 m72 m74.7 m


5.3 m5.2 m5.4 m6.8 m7 m7 m
USDFY, 2015FY, 2016

Net Income

(30.8 m)(83.3 m)

Accounts Receivable

(2.2 m)


2.5 m(3.2 m)

Accounts Payable

4.8 m3 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(5.8 m)(9.4 m)(12.6 m)(26.5 m)(25.8 m)(17.1 m)


1.7 m2.7 m2.5 m4.4 m5.7 m5.6 m

Accounts Payable

1.3 m2.4 m3.5 m3.3 m7.8 m7 m
Y, 2017

Financial Leverage

7.9 x
Show all financial metrics

Neos Therapeutics Market Value History

Traffic Overview of Neos Therapeutics

Neos Therapeutics News and Updates

BRIEF-Neos Therapeutics Qtrly loss per share $1.65

* Neos Therapeutics announces second quarter 2016 financial results

Neos Therapeutics Company Life and Culture

You may also be interested in